1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr S P Dingemans
|
|
b)
|
Position/status
|
Executive Director
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019 on Ordinary Shares
held in the Company's Performance Share Plan, subject to a 2-year
holding period.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.6560
|
2220.684
|
||
£15.6560
|
2397.921
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
4618.605
£15.6560
|
|
e)
|
Date
of the transaction
|
2019-04-12
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: April
16, 2019
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|